argenx

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel mechanism of action for CIDP treatment in more than 30 years. 20 June 2025 -- Amsterdam, the...

UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)

28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment...

argenx Announces MHRA Licensing of Subcutaneous VYVGART (efgartigimod alfa) for generalised Myasthenia Gravis

VYVGART is now licensed for both intravenous (IV) and self-administered subcutaneous (SC) use in the UK 7 February 2024 -- Gerrards Cross, UK -- argenx UK, part of argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that the Medicines and Healthcare products Regulatory Agency...
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG